Aug 17, 2013 by Brian Orelli, PhDThe Good and Bad of a Competitor's FailureSometimes, one man's trash is just another man's trash.
Aug 14, 2013 by Brian Orelli, PhDDreamboat Data? Not Exactly.MannKind's Afrezza data is good enough for approval, but nothing to get too excited about.
Aug 13, 2013 by Brian Orelli, PhDDid We Hear This Biotech's Last Earnings Call Ever?A sale of the company looks likely, but priced in.
Aug 11, 2013 by Brian Orelli, PhDA Good Drug That's Too Risky to BuyMannKind's inhaled insulin, Afrezza, looks like it'll pass its phase 3 program, but the risks don't end there.
Aug 11, 2013 by Brian Orelli, PhDCan the Newly Discovered Obesity Genes Help You Lose Weight?Not right now, but at least you can blame your parents.
Aug 9, 2013 by Brian Orelli, PhDThe Easiest Prediction in Biotech This SummerMannKind's extended phase 3 program has a high likelihood of success.
Aug 8, 2013 by Brian Orelli, PhDThe Most Important Number for This Drug LaunchARIAD launches its leukemia drug Iclusig, but sales aren't what's most important.
Aug 7, 2013 by Brian Orelli, PhDVIVUS: New Management, Same Ideas?VIVUS' new management highlights the same problems that the old one did without any real solutions.
Aug 2, 2013 by Brian Orelli, PhDNothing to See Here, No Huge Sales YetArena Pharmaceuticals reports a month of sales; investors should be focused on the future.
Jul 31, 2013 by Brian Orelli, PhDBy the Way, Pfizer Reported EarningsPfizer's reorganization trumps earnings in the news cycle.
Jul 31, 2013 by Brian Orelli, PhDObesity Drug Competition at LastArena and VIVUS will both report sales figures for the obesity drugs in the coming weeks.
Jul 30, 2013 by Brian Orelli, PhDStrange Biotech BedfellowsOver-the-counter drugmaker Perrigo proposes to buy Ireland's Elan.
Jul 26, 2013 by Brian Orelli, PhDVertex Drops After Hepatitis-C Drug Put on Hold The FDA puts Vertex's VX-135 on a partial clinical hold.
Jul 25, 2013 by Brian Orelli, PhDExpanding P/E Saved This Pharma InvestmentBristol-Myers earnings guidance falls below 2009 levels, but shares are up substantially since then.
Jul 24, 2013 by Brian Orelli, PhDNo 8th Indication for You, HumiraAn FDA advisory committee shoots down expanding AbbVie's Humira to treat axial spondyloarthritis.
Jul 24, 2013 by Brian Orelli, PhDFDA Delays Decision (i.e., Reverts to Norm)FDA says it won't make a decision about the approvability of Sarepta Therapeutics' drug until it actually applies for approval.
Jul 23, 2013 by Brian Orelli, PhDA Biotech's Swelling ValuationBioCryst shoots up after its hereditary angioedema drug BCX4161 posts positive phase 1 data.
Jul 19, 2013 by Brian Orelli, PhDGreat Job, Now You're FiredFirst Manhattan succeeds in overthrowing VIVUS' board.
Jul 18, 2013 by Brian Orelli, PhD3.5 Potential Suitors for OnyxAll four companies look like good fits.
Jul 16, 2013 by Brian Orelli, PhDVIVUS Extends Olive Branch, Follows With FistThe proxy fight continues.
